Perfuze Secures the US FDA’s 510(k) Clearance for its Zipline Access Catheters
Shots:
- The US FDA has granted 510(k) clearance to Zipline Access Catheters to treat acute ischemic strokes
- Zipline improves delivery of a large (070) & superbore (088) aspiration catheter to enhance trackability & simplify neuro-interventional procedures for faster as well as more efficient stroke treatment. Zipline also optimizes clot removal & improves success rates with added support & easy navigation
- Additionally, Perfuze has secured $23.9M (€22M) from existing investors, incl. Earlybird, EQT Life Sciences, Seroba, & SV Health, to advance clinical and R&D activities, plus to support limited market release of Zipline & Millipede catheters, which are now launched in the US
Ref: BusinessWire | Image: Perfuze
Related News:- Ultromics’ EchoGo Amyloidosis Receives the US FDA’s Breakthrough Device Designation to Detect Cardiac Amyloidosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
